Compare stocks

M1 Kliniken AG, headquartered in Berlin, Germany, specializes in aesthetic medicine and plastic surgery services. Operating under the "M1 Med Beauty" brand, the company offers treatments such as breast augmentation, eyelid lifts, liposuction, and non-invasive procedures like hyaluronic acid and botulinum toxin injections. As of 2023, M1 Kliniken operates 58 specialist centers across ten countries, including Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, Hungary, Bulgaria, Romania, and Australia. The company also manages the M1 Schlossklinik in Berlin, a facility with six operating theaters and 35 beds. M1 Kliniken's strategic focus on specialization and centralized purchasing enables it to offer high-quality medical services at competitive prices.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.